Results 1 to 10 of about 10,851,050 (358)

Combination therapy [PDF]

BJOG: An International Journal of Obstetrics & Gynaecology, 2005
Objective  Inhibiting preterm labour at extremely early gestations.Design  Observational study. Case reports.Setting  Perinatal Centre Lund University Hospital, South Sweden.Population  Twenty‐five women (13 cases with intact membranes and 12 cases with ruptured) with threatened preterm labour and advanced cervical status before 26 completed weeks of ...
Choy, E H, Paulus, H E
  +5 more sources

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.

New England Journal of Medicine, 2022
BACKGROUND First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously treated patients with advanced esophageal
Y. Doki, J. Ajani, Ken Kato, Jianming Xu, L. Wyrwicz, S. Motoyama, T. Ogata, H. Kawakami, Chih-Hung Hsu, A. Adenis, F. El hajbi, M. Di Bartolomeo, M. Braghiroli, E. Holtved, S. A. Ostoich, H. R. Kim, Masaki Ueno, Wasat Mansoor, Wen-Chi Yang, Tianshu Liu, J. Bridgewater, T. Makino, I. Xynos, Xuan Liu, M. Lei, K. Kondo, A. Patel, J. Gricar, I. Chau, Y. Kitagawa   +29 more
semanticscholar   +1 more source

Multifunctional metal-organic framework (MOF)-based nanoplatforms for cancer therapy: from single to combination therapy

Theranostics, 2023
Cancer remains a severe threat to human health. To date, although various therapeutic methods, including radiotherapy (RT), chemotherapy, chemodynamic therapy (CDT), phototherapy, starvation therapy, and immunotherapy, have entered a new stage of rapid ...
Jie Yang, Dihua Dai, Xi Zhang, Lesheng Teng, Lianjun Ma, Ying‐Wei Yang   +5 more
semanticscholar   +1 more source

Radiation-induced tumor immune microenvironments and potential targets for combination therapy

Signal Transduction and Targeted Therapy, 2023
As one of the four major means of cancer treatment including surgery, radiotherapy (RT), chemotherapy, immunotherapy, RT can be applied to various cancers as both a radical cancer treatment and an adjuvant treatment before or after surgery.
Siyu Guo, Yihan Yao, Yang Tang, Zengfeng Xin, Dang Wu, C. Ni, Jian Huang, Q. Wei, Ting Zhang   +8 more
semanticscholar   +1 more source

Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy

Microorganisms, 2023
Influenza infection is serious and debilitating for humans and animals. The influenza virus undergoes incessant mutation, segment recombination, and genome reassortment.
Sania Batool, Santosh Chokkakula, Min-Suk Song   +2 more
semanticscholar   +1 more source

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Journal of Hematology & Oncology, 2022
Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment in clinical practice and have great potential.
Mengli Wu, Qianrui Huang, Yao Xie, Xuyi Wu, Hongbo Ma, Yiwen Zhang, Yong Xia   +6 more
semanticscholar   +1 more source

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier

Cancer Cell International, 2022
Recently, immune checkpoint inhibitors (ICIs) therapy has become a promising therapeutic strategy with encouraging therapeutic outcomes due to their durable anti-tumor effects.
S. Vafaei, A. Zekiy, R. A. Khanamir, B. Zaman, Arman Ghayourvahdat, Hannaneh Azimizonuzi, M. Zamani   +6 more
semanticscholar   +1 more source

Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms.

NEJM Evidence, 2022
BACKGROUND Pneumonia and bloodstream infections (BSI) due to extensively drug-resistant (XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem-resistant Enterobacterales (CRE) are associated with high mortality rates, and therapeutic ...
K. Kaye, D. Marchaim, V. Thamlikitkul, Y. Carmeli, Cheng-Hsun Chiu, G. Daikos, S. Dhar, E. Durante-Mangoni, A. Gikas, A. Kotanidou, M. Paul, E. Roilides, M. Rybak, M. Samarkos, M. Sims, D. Tancheva, S. Tsiodras, D. Kett, G. Patel, D. Calfee, L. Leibovici, L. Power, Sylvia Munoz-Price, K. Stevenson, L. Susick, Katie A. Latack, J. Daniel, Christine Chiou, G. Divine, Varduhi Ghazyaran, J. Pogue   +30 more
semanticscholar   +1 more source

Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study

Cell Reports Medicine, 2022
Summary To parallelly compare the efficacy of neoadjuvant immunotherapy (tislelizumab), neoadjuvant chemotherapy (gemcitabine and cisplatin), and neoadjuvant combination therapy (tislelizumab + GC) in patients with muscle-invasive bladder cancer (MIBC ...
Jiao Hu, Jinbo Chen, Zhenyu Ou, Haige Chen, Zheng Liu, Minfeng Chen, Ruiyun Zhang, Anze Yu, Rui Cao, Enchong Zhang, Xi Guo, B. Peng, D. Deng, Chunliang Cheng, Jinhui Liu, Huihuang Li, Yihua Zou, Ruoping Deng, Gang Qin, Wenze Li, Lue Wang, Tao Chen, Xiaming Pei, G. Gong, Jiansheng Tang, Belaydi Othmane, Z. Cai, Chunyu Zhang, Zhi Liu, X. Zu   +29 more
semanticscholar   +1 more source

Independent Drug Action in Combination Therapy: Implications for Precision Oncology

Cancer Discovery, 2022
Combination therapies are superior to monotherapy for many cancers. This advantage was historically ascribed to the ability of combinations to address tumor heterogeneity, but synergistic interaction is now a common explanation as well as a design ...
D. Plana, A. Palmer, P. Sorger
semanticscholar   +1 more source